Slide 1: Corporate Presentation: Financial Results Q3 - FY 2005
§) Corporate Presentation | Financial Results Q3 - FY 2005 ©0 0 @ 1/19
Slide 2: Disclaimer
$ Biocon Disclaimer Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking sta
Slide 3: Biocon Group - Corporate Structure
Biocon Group - Corporate Structure Employees / 13% | 65% | $ Biocon | 22% S Biocon t 100% 51% Syngene Biocon Custom Research Biopharmaceuticals Y U 100% Clinigene Clinical Development
Slide 4: Biocon: A fully integrated bio-pharma company
BS Biocon: A fully integrated bio-pharma company Syngene Clinigene BSS Discovery Research Clinical Development , FTEs (No IP) » Clinical Program for in-house product (eg. Insulin, h-R3) , Projects (Royalties / Milestones) » Clinical Registries (eg. Diabetes, Oncology) , Partnering (Shared IP) , CRO:
Slide 5: Biocon's Technology Edge
BS Biocon Biocon's Technology Edge sinsuin « lan Recombinant . es © Immuno- MABs & animal Proteins suppressants cell culture Immuno- e suppressants Statins © Enzymes © r-DNA Proteins r-Human Insulin Streptokinase GCSF Statins Immuno- © Monoclonal suppressants Anitibodies Small Molecules Statins © An
Slide 6: Delivering on a long term vision of proprietary products
Delivering on a long term vision of proprietary products New drug discovery & development , Products with large global markets , Near term patent expiry G . , Fermentation derived eneric molecules Biopharmaceuticals , High technology barriers , High regulatory barriers Funding long term discovery re
Slide 7: Oral Insulin
Oral Insulin Partnership with Nobex to develop and commercialize Oral Insulin Product positioned for post prandial blood glucose control in both early & advanced Type 2 Diabetics Multi Billion Dollar Market Opportunity
Slide 8: Alternative Insulin Competitive Landscape
S Biocon Alternative Insulin Competitive Landscape Pre-Cllinical Inbdled (QDose/Bw cs) Phase | |_Inhaled _| 1 for al Insulin (BioSante) Inhaled #hsulin (Alkernes/Lill 4 (Alke ly e ntesulin Oral (Coremed) Technosphgre Insulih Systerf Exubera (Mannkind) Inhaled Insulin i a) Oral Insulin a (Bipcon / No
Slide 9: Monoclonal Antibodies - Vaccinex
S Biocon Monoclonal Antibodies - Vaccinex » Partnership with Vaccinex to discover and develop fully Human Antibodies » Develop Novel Antibodies - Biocon responsible for Proof of Concept, Product and Process Development - Joint Responsibility for Global Clinical Trials and Marketing Product Monoclona
Slide 10: Antibody - Vaccinex
Antibody - Vaccinex Humanization 95% Human Antibody Transgenic Mice Re-engineered Immune System 100% Human Antibody Phage Display Patibody Libraries Created in | Bacteria 100% Human Antibody Not fully human MAb Tolerance issues with homologous proteins o Tolerance issues with homologous proteins o B
Slide 11: hR3 - CIMAB
hR3 - CIMAB » Partnership with CIMAB » Antibody targeted against Head & Neck Cancer » Phase IIB Clinical Trials in India » Clinical Trials planned for Glioblastoma & Non Small Cell Lung Carcinoma (NSCLC)
Slide 12: Growth Drivers
Growth Drivers MAbs Immuno- suppressants CRO Insulin Research Services Statins CI@O)C) |
Slide 13: Financial Highlights & Analysis
== Financial Highlights & Analysis Q3 - FY 2005 CI@O)C) |
Slide 14: Months Highlights
$ Biocon 9 Months Highlights Revenues grew by 39% to Rs. 550 crores, Q3 revenues at Rs. 183 crores PAT grew 63% to Rs. 155 crores, Q3 PAT at Rs. 50 crores Shareholder's funds increase to Rs. 721 crores All sectors performed well (Biopharmaceuticals, enzymes & research services) Insugen successfully
Slide 15: Revenue Break-up: Apr - Dec
Revenue Break-up: Apr - Dec FY 04 FY 05 M3 Custom Research HM Enzymes [2] Pharma HM Other Income Hl Total Consolidated Financials as per Indian GAAP
Slide 16: Revenue Growth Dynamics
$ Biocon Revenue Growth Dynamics Contract research 75% & Newresearch facilities operational Enzymes 36% & Speciality Enzymes continue to generate significant interest in US & Europe Biopharmaceuticals 33% Launch of Recombinant Human Insulin Consolidated Financials as per Indian GAAP
Slide 17: Markets: Apr - Dec
Markets: Apr - Dec FY 04 FY 05 [4 Domestic Ml Exports Consolidated Financials as per Indian GAAP
Slide 18: Profit: Apr - Dec
Profit: Apr - Dec Revenues - Improved Yields & Sales Mix EBDITA - Growth in Employees & Inc in Salaries - Increase in SG&A Exps - Profits from 100% EOUs not taxable PAT Growth - 63% Consolidated Financials as per Indian GAAP CI@O)C) |
Slide 19: Thank You
== Thank You CIMOJO) |